Unlocking Safer, More Efficient Delivery to Targeted Brain Regions by Advancing Direct, & Systemic Delivery to the CNS Via TfR1 & Beyond
Despite milestones such as Roche’s Trontinemab Brainshuttle™ achieving robust amyloid clearance, challenges remain in reaching targeted brain regions, improving predictive modelling, ensuring efficacy and penetrance, and developing safer, targeted delivery approaches.
Join 100+ industry experts spanning neuroscientists, chemists, device engineers, conjugation scientists, DMPK experts, delivery specialists, and more at the 7th CNS Drug Delivery Summit to collaborate, network, and learn cutting-edge strategies that are tackling the unique challenges in gaining access to the brain.
Secure your place here or get in touch with the team – info@hansonwade.com